SAKK 06/14: A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy
Laufzeit: 01.01.2017 - 31.12.2018
Kurzfassung
Trial objectives:
Phase I
To determine safety, tolerability and the recommended phase II dose (RP2D) of intravesical VPM1002BC instillations in patients with recurrence of non-muscle-invasive bladder cancer (NMIBC) after TURB and standard BCG therapy.
Phase II
To investigate the efficacy, safety, tolerability and immunogenicity of intravesical VPM1002BC instillations in patients with recurrence of non-muscle-invasive bladder cancer (NMIBC) after TURB and standard BCG therapy.
